| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GCLM; GCS light chain; GLCLR; Glutamate cysteine ligase regulatory subunit;;GCLM |
| WB Predicted band size | 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human GCLM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于GCLM抗体的参考文献示例(注：文献标题和作者为虚构，供参考)：
1. **标题**: "GCLM antibody-based detection of oxidative stress response in Parkinson's disease models"
**作者**: Lee S, et al.
**摘要**: 该研究利用特异性GCLM抗体，在小鼠帕金森病模型中验证GCLM蛋白表达与氧化应激的关系，发现中脑多巴胺能神经元中GCLM水平显著降低，提示其参与疾病病理机制。
2. **标题**: "Development of a high-affinity monoclonal antibody for human GCLM and its application in cancer cell lines"
**作者**: Zhang Y, et al.
**摘要**: 报道一种新型抗人GCLM单克隆抗体的开发，通过免疫印迹和免疫荧光技术，在肺癌细胞系中证实GCLM表达与化疗耐药性的正相关性，为癌症治疗提供潜在靶点。
3. **标题**: "GCLM knockout mice reveal compensatory mechanisms in glutathione synthesis via antibody-based tissue analysis"
**作者**: Rodriguez A, et al.
**摘要**: 使用GCLM抗体分析基因敲除小鼠的肝、肾组织，发现GCLM缺失导致GCL催化亚基(GCLC)表达上调，揭示了谷胱甘肽合成的代偿调控通路。
(注：以上文献为示例，实际引用需检索PubMed等数据库获取真实文献。)
The glutamate-cysteine ligase modifier subunit (GCLM) is a critical regulatory component of the glutamate-cysteine ligase (GCL) enzyme, which catalyzes the rate-limiting step in glutathione (GSH) biosynthesis. GCL functions as a heterodimer, comprising a catalytic subunit (GCLC) and a modifier subunit (GCLM). GCLM enhances the catalytic efficiency of GCLC by lowering its Km for ATP and increasing its Ki for GSH feedback inhibition, thereby fine-tuning cellular antioxidant capacity. As glutathione is the primary intracellular antioxidant, GCLM plays a pivotal role in maintaining redox homeostasis and defending against oxidative stress.
GCLM antibodies are immunological tools developed to detect, quantify, and study the expression, localization, and function of the GCLM protein. These antibodies are widely utilized in research exploring oxidative stress-related pathologies, including neurodegenerative diseases (e.g., Parkinson’s, Alzheimer’s), cardiovascular disorders, cancer, and metabolic syndromes. They enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess GCLM levels in tissues or cultured cells under varying oxidative conditions.
Studies using GCLM antibodies have revealed its involvement in adaptive responses to environmental toxins, inflammation, and chemotherapeutic agents. Polymorphisms in the GCLM gene, linked to reduced GSH synthesis, are associated with increased disease susceptibility, making GCLM a potential biomarker for oxidative stress-related conditions. Research continues to explore therapeutic strategies targeting GCLM to modulate cellular antioxidant defenses, highlighting the antibody’s importance in both mechanistic and translational investigations.
×
